arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

download Export Data

Neuphoria Therapeutics Inc.

NEUP

$3.94 0.00 (+0.13%) at close

13 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Neuphoria Therapeutics Inc. faces fundamental challenges with weakness in Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $21.3M

Dividend Yield —

Revenue Growth —

Op. Margin None

ROIC -3.9% ↗

FCF / Share $-0.62 ↗

Trailing P/E —

Price / Book 0.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

13-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$-13.27K

↓ -100.1% —

Net Income Profit after all expenses

$-9.91M

↓ -1130.9% —

FCF / Share Free cash flow per share

$-0.62

↑ +56.5% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability

Returns ↑

Financial Health ↑

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q3 FY2026 Mar 31, 2026 10-Q ↗	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q4 FY2022 Jun 30, 2022 10-K ↗
EPS Growth YoY (%)	N/M	N/M	—	-69.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	76.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-1130.9% Weak ↓ Weak Declining Year-over-year change in net income	-1130.9% Weak ↓ Weak Declining Year-over-year change in net income	-1130.9% Weak ↓ Weak Declining Year-over-year change in net income	-230.6% Weak ↓ Weak Declining Year-over-year change in net income	85.3% Excellent → Excellent Stable Year-over-year change in net income	85.3% Excellent Excellent Year-over-year change in net income	85.3% Excellent Excellent Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	—	—	-106919.8% Weak Weak Year-over-year change in free cash flow	—	—	—	46.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	Q3 FY2026 Mar 31, 2026 10-Q ↗	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q4 FY2022 Jun 30, 2022 10-K ↗
Operating Margin (%) (%)	—	—	—	—	79.8% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+432%)	—	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	6.4% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.9% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	2.9% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.7% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.6% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	14.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.3% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.6% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	—	—	—	—	-5.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-145%)	-121.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1112%)	—	—	—	—	—	—	—
FCF / Net Income (x)	0.34x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.65x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.38x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.40x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	5.51x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.12x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q3 FY2026 Mar 31, 2026 10-Q ↗	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q4 FY2022 Jun 30, 2022 10-K ↗
Return on Invested Capital (%)	-3.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-13.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-45.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	46.4% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-27.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-18.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-30.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-23.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-31.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-3.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-11.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	39.0% Excellent ↑ Excellent Improving Operating profit relative to total assets Optimal: > 10%	-20.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-15.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-19.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	-33.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-324%)	-33.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-322%)	-79.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-628%)	-46.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-412%)	-3.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-121%)	-5.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-139%)	-4.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-131%)	-15.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-202%)	-30.5% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-303%)	-28.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-287%)	-31.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-312%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q3 FY2026 Mar 31, 2026 10-Q ↗	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q4 FY2022 Jun 30, 2022 10-K ↗
Net Debt (USD)	$-19.44M	$-22.17M	$-13.65M	$-14.21M	$-17.04M	$-4.34M	$-8.08M	$-12.61M	$-8.43M	$-10.15M	$-8.14M	$-12.10M	—

📊 What does each share earn? 6 metrics

Metric	Q3 FY2026 Mar 31, 2026 10-Q ↗	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q4 FY2022 Jun 30, 2022 10-K ↗
Revenue per Share (USD)	—	—	—	—	$8.73	$0.42	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.09	$0.41	$-4.41	$-5.79	$6.55	$-1.23	$0.00	$-3.42	$-2.83	$-5.31	$0.00	—	—
Free Cash Flow per Share (USD)	$-0.62	$-1.42	$-1.69	—	—	—	$-0.00	—	$-3.36	$-4.60	$-0.00	—	—
Book Value per Share (USD)	$5.47	$5.52	$5.31	$9.60	$14.02	$8.44	$0.01	$15.84	$18.29	$22.74	$0.01	$0.01	—
Tangible Book Value per Share (USD)	$3.03	$3.07	$-0.34	$2.81	$6.78	$0.13	$0.00	$3.02	$9.50	$12.43	$0.01	$0.00	—
Basic Weighted Avg Shares (shares)	5.41M	4.54M	2.25M	—	1.72M	1.58M	2.81B	—	981,040	857,264	1.50B	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q3 FY2026 Mar 31, 2026 10-Q ↗	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q4 FY2022 Jun 30, 2022 10-K ↗
Working Capital (USD)	$20.14M	$20.80M	$8.83M	$10.82M	$15.54M	$2.26M	$5.88M	$9.36M	—	—	—	$10.59M	—
Total Equity (USD)	$29.42M	$29.70M	$12.51M	$19.00M	$26.00M	$13.75M	$17.07M	$17.49M	$17.95M	$19.50M	$17.23M	$22.01M	$39.23M

📋 What is driving earnings? 3 metrics

Metric	Q3 FY2026 Mar 31, 2026 10-Q ↗	Q2 FY2026 Dec 31, 2025 10-Q ↗	Q1 FY2026 Sep 30, 2025 10-Q ↗	Q4 FY2025 Jun 30, 2025 10-K ↗	Q3 FY2025 Mar 31, 2025 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Sep 30, 2024 10-Q ↗	Q4 FY2024 Jun 30, 2024 10-K ↗	Q3 FY2024 Mar 31, 2024 10-Q ↗	Q2 FY2024 Dec 31, 2023 10-Q ↗	Q1 FY2024 Sep 30, 2023 10-Q ↗	Q4 FY2023 Jun 30, 2023 10-K ↗	Q4 FY2022 Jun 30, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	$-13.27K	$15.00M	$662.72K	—	—	—	—	—	—	—
Net Income, GAAP (USD)	$-9.91M	$-9.91M	$-9.91M	$-8.88M	$-804.79K	$-804.79K	$-804.79K	$-2.69M	$-5.47M	$-5.47M	$-5.47M	—	—
Operating Cash Flow (USD)	$-3.34M	$-6.44M	$-3.79M	$-3.59M	—	—	$-4.43M	$-3.01M	$-3.30M	$-3.95M	$-4.43M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 13 quarters

Neuphoria Therapeutics Inc.

Analytical Summary

13-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NEUP with peers